Looking at a New Treatment for Advanced Stomach and Esophagus Cancer

Recruiting · Phase 2 · Gastro-Intestinal Cancer · New Jersey

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial studies a treatment called sFOLFOXIRI for people with advanced gastroesophageal cancer. The goal is to see how effective this treatment is and how well patients tolerate it. Researchers want to find out if this new combination of chemotherapy works better than standard treatments. They will also look at how long patients can live without their cancer getting worse.

The trial's ID number is NCT05332002. This is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The study is FDA-regulated, and the researchers hope to include about 38 participants.

Who can join

Adults aged 18 and older can join this trial. It is open to both men and women who have a specific type of cancer that is not HER2 positive. Participants must be in good health overall and cannot have received prior treatment for their cancer in the metastatic stage. The trial team will confirm eligibility for each person who wishes to join.

Condition

Gastro-Intestinal Cancer

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in this trial will receive the same treatment, which is a combination of two types of chemotherapy given in a cycle lasting four weeks. They will alternate between two different regimens: FOLFOX and FOLFIRI. Some participants may also receive an additional treatment called nivolumab. The treatment will be given in a safe and monitored way over several cycles.